TGF-β and TNF-α producing effects of losartan and amlodipine on human mononuclear cell culture

Nephrology

Volumn 10, Issue 5, 2005, Pages 478-482

  Kaynar, Kubra ^a   Ulusoy, Sukru ^a   Ovali, Ercument ^a   Vanizor, Birgul ^a   Dikmen, Tamer ^a   Gul, Semih ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Amlodipine; Losartan; Mononuclear cell culture; TGF ; TNF

Indexed keywords

AMLODIPINE BESYLATE; LOSARTAN POTASSIUM; METHYLTHIAZOLETETRAZOLIUM; TETRAZOLIUM; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INCUBATION TIME; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; CELLS, CULTURED; HUMANS; LEUKOCYTES, MONONUCLEAR; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28444461035     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00462.x     Document Type: Article

References (29)

1. Von Baeyer H, Hopfenmuller W, Riedel E. Atherosclerosis: Current concepts of pathophysiology and pharmacological intervention based on trial outcomes. Clin. Nephrol. 2003; 60: 31-48.
2. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995; 25: 155-61.
3. Simon BC, Noll B, Maisch B. Endothelial dysfunction: Assessment of current status and approaches to therapy. Herz 1999; 24: 62-71.
4. Smith JK, Dykes R, Douglas JE. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722-7.
5. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988; 242: 97-9.
6. Mancini GB. Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT. Can. J. Cardiol. 2000; 16: 5-7.
7. Dahlöf B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
8. Wu XJ, Huang L, Song DL. Effects of endothelial cell growth states on the proliferation and migration of vascular smooth muscle cells in vitro. Sheng Li Wue Bao 2003; 55: 554-9.
9. Robertson AKL, Rudling M, Zhou X. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Ýnvest. 2003; 112: 1342-50.
10. Grainger DJ, Kemp PR, Liu AC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-62.
11. Argmann CA, Van Den Diepstraten CH, Sawyez CG. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 2011-18.
12. Byington RP, Miller ME, Herrington D et al. Rationale, design and baseline characteristics of the prospective randomized evaluation of the vascular effects of norvasc trial (PREVENT). Am. J. Cardiol. 1997; 80: 1087-90.
13. Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.
14. Harano Y, Kagayama A, Hirose J. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 1995; 44: 315-19.
15. Baba T, Neugebauer S. The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidemic drugs on insulin sensitivity. Drugs 1994; 47: 383-404.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-90.
17. Tristano A, Eugenia Chollet M, Wilson ML. Telomerase activity in peripheral blood leukocytes from patients with essential hypertension. Med. Clin. 2003; 120: 365-9.
18. Mohler ER, Sorensen LC, Ghali JK. Role of cytokines in the mechanism of action of amlodipine: The PRAISE heart failure trial. Prospective randomized amlodipine survival evaluation. J. Am. Coll. Cardiol. 1991; 30: 35-41.
19. Matsumori A, Ono K, Nishio R. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 2000; 12: 294-7.
20. Fukuzawa M, Satoh J, Ohta S et al. Modulation of tumor necrosis factor-α production with anti-hypertensive drugs, Immunopharmacology 2000; 48: 65-74.
21. Pirich C, Schmid P, Fitscha P. Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press. 1994; 3: 75-80.
22. Chaudri G, Clark IA. Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor. J. Immunol. 1989; 143: 1290-94.
23. Yu T, Morita I, Shimokado K. Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction. Hypertension 2003; 42: 329-34.
24. Kranzhofer R, Browatzki M, Schmidt J. Angiotensin II activates the pro inflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem. Biophys. Res. Commun. 1999; 257: 826-8.
25. Di Paolo SD, Schena A, Stallone G. Captopril enhances transforming growth factor (TGF)-β1 expression in peripheral blood mononuclear cells: A mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation 2002; 74: 1710-15.
26. Nataraj C, Oliverio MI, Mannon RB. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J. Clin. Invest. 1999; 104: 1693-701.
27. Klahr S, Morrissey J. Angiotensin II and gene expression in the kidney. Am. J. Kidney Dis. 1998; 31: 171-6.
28. Tashiro H, Shimokawa H, Yamamoto K. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron. Artery Dis. 1997; 8: 143-7.
29. Park S, Yang WS, Lee SK. TGF-β1 down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. Nephrol. Dial. Transplant. 2000; 15: 596-604.